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Carbapenem resistance in Gram-negative bacteria is on the rise in the United States. A regional network was established to study
microbiological and genetic determinants of clinical outcomes in hospitalized patients with carbapenem-resistant (CR) Kleb-
siella pneumoniae in a prospective, multicenter, observational study. To this end, predefined clinical characteristics and out-
comes were recorded and K. pneumoniae isolates were analyzed for strain typing and resistance mechanism determination. In a
14-month period, 251 patients were included. While most of the patients were admitted from long-term care settings, 28% of
them were admitted from home. Hospitalizations were prolonged and complicated. Nonsusceptibility to colistin and tigecycline
occurred in isolates from 7 and 45% of the patients, respectively. Most of the CR K. pneumoniae isolates belonged to repetitive
extragenic palindromic PCR (rep-PCR) types A and B (both sequence type 258) and carried either blaKPC-2 (48%) or blaKPC-3
(51%). One isolate tested positive for blaNDM-1, a sentinel discovery in this region. Important differences between strain types
were noted; rep-PCR type B strains were associated with blaKPC-3 (odds ratio [OR], 294; 95% confidence interval [CI], 58 to 2,552;
P < 0.001), gentamicin nonsusceptibility (OR, 24; 95% CI, 8.39 to 79.38; P < 0.001), amikacin susceptibility (OR, 11.0; 95% CI,
3.21 to 42.42; P < 0.001), tigecycline nonsusceptibility (OR, 5.34; 95% CI, 1.30 to 36.41; P  0.018), a shorter length of stay (OR,
0.98; 95% CI, 0.95 to 1.00; P  0.043), and admission from a skilled-nursing facility (OR, 3.09; 95% CI, 1.26 to 8.08; P  0.013).
Our analysis shows that (i) CR K. pneumoniae is seen primarily in the elderly long-term care population and that (ii) regional
monitoring of CR K. pneumoniae reveals insights into molecular characteristics. This work highlights the crucial role of ongoing
surveillance of carbapenem resistance determinants.
Antimicrobial resistance is “one of the greatest threats to hu-man health worldwide” (1). The additional annual cost asso-
ciated with treating antimicrobial-resistant pathogens in the
United States is estimated to be between $21 billion and $34 bil-
lion (1). Carbapenem-resistant (CR) Klebsiella pneumoniae infec-
tions are especially worrisome, as very few treatment options re-
main for patients and outcomes are generally poor.
Central to the control of the problem of CR K. pneumoniae is
the institution of effective regional surveillance networks. To ad-
dress this, we formed a multicenter consortium to prospectively
study the epidemiology, molecular characteristics, and clinical
outcomes of infections due to CR K. pneumoniae in hospitalized
patients in northeastern Ohio. Here, we report the initial findings
of this consortium and describe the genomic analysis of a
blaNDM-1-carrying strain that was discovered as a result of orga-
nized surveillance.
MATERIALS AND METHODS
Establishment of the Great Lakes CR K. pneumoniae consortium. A
multicenter consortium was established that consists of three health care
systems that include 18 hospitals serving more than 2 million people in
northeastern Ohio. These included both community-based hospitals and
tertiary-care referral centers ranging in size from 25 to 1,400 beds. Each
health care system participating in this study is served by one or more
clinical microbiology laboratories that process an average of 200,000 bac-
terial cultures from clinical samples yearly. None of the hospitals per-
formed screening for asymptomatic carriage of CR K. pneumoniae during
the study period.
Microbiology. We defined CR K. pneumoniae as isolates with de-
creased susceptibility to meropenem or imipenem (MIC, 1 g/ml).
Bacterial identification to the species level and routine antimicrobial sus-
ceptibility testing were performed with the MicroScan (Siemens Health-
care Diagnostics) or Vitek2 (bioMérieux) automated system supple-
mented by additional testing if required. In this study, MIC results were
interpreted according to breakpoints defined by the Clinical and Labora-
tory Standards Institute (CLSI), with the exception of tigecycline and
colistin, where criteria set forth by the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST) were used because of a lack of
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validated CLSI breakpoints. At each site, study personnel were notified by
the local microbiology laboratory upon the identification of a CR K. pneu-
moniae isolate from a hospitalized patient. Clinical data were obtained
from the medical record and entered into a centralized clinical database.
The Institutional Review Boards of all of the health care systems involved
approved this study.
Patients. All of the hospitalized patients from whom CR K. pneu-
moniae was isolated were included if their hospitalization began and
ended within the study period, which lasted from 12/24/2011 until 3/1/
2013. All of the analyses are based on the first culture positive for CR K.
pneumoniae during the index hospitalization of each individual patient.
Definitions of infection. A patient with a culture positive for CR K.
pneumoniae was deemed to have an infection if CR K. pneumoniae was
isolated from blood or any other sterile source. For patients with positive
respiratory cultures, the criteria outlined by the American Thoracic Soci-
ety and the Infectious Diseases Society of America were used (2, 3). For
patients with positive cultures from urine or surgical wounds, the CDC
National Healthcare Safety Network criteria were applied (4). Patients
with cultures from nonsurgical wounds were considered infected only if
the treating physician documented infection in the medical record and
evidence of systemic inflammation on the day the positive culture was
documented; this was defined as an abnormal systemic white cell count
(either 10  103 or 4  103 cells/l) and/or an abnormal body tem-
perature (either 99.5°F or 96°F). All of the other culture episodes were
designated colonizations.
Clinical data collection and definitions. Clinicaldatacollectionincluded
the following: demographics, prehospital origin and posthospital disposition, co-
morbidities, including the Charlson comorbidity index (5), CR K. pneumoniae
treatment variables, previous antibiotic use, and culture site-specific vari-
ables. Previous antibiotic use was recorded as the class of antibiotic with
documented exposure in the 14 days leading up to the day of the first
positive culture. Infections were defined as nosocomial if the first CR K.
pneumoniae-positive culture was obtained 48 h after hospital admis-
sion. Health care-associated infections were defined as infections in pa-
tients admitted from long-term care facilities or other hospitals who had a
first CR K. pneumoniae-positive culture within the first 48 h. Patients with
a first CR K. pneumoniae-positive culture within 48 h who were admitted
from home were deemed to have community-acquired infections. Renal
insufficiency was defined as any serum creatinine level of 2 mg/dl. The
Pitt bacteremia score (PBS) was calculated as described previously (6). If
patients were intubated and sedated and no further information on men-
tal status was available, the mental status was coded as “stuporous” for the
purpose of calculating this score only. This score has been validated as a
predictor of the outcome of CR K. pneumoniae bloodstream infection (7).
Molecular detection of carbapenemases in CR K. pneumoniae. All of
the available CR K. pneumoniae isolates were sent to a central research
laboratory in this consortium for further testing. PCR amplification of the
blaKPC, blaNDM blaVIM, blaIMP, and blaOXA-48 genes was performed with
established primers and methods (8, 9). Amplicons were sequenced at a
commercial sequencing facility (MCLAB, San Francisco, CA) and ana-
lyzed as previously described (8, 9).
Molecular typing of CR K. pneumoniae. Genetic similarity among
isolates was investigated by repetitive extragenic palindromic PCR (rep-
PCR) by using the DiversiLab strain typing system (Bacterial BarCodes,
bioMérieux, Athens, GA). Isolates with 95% similarity were considered
to be of the same rep-PCR type. Rep-PCR has previously been shown to
have adequate discriminatory power for CR K. pneumoniae strain typing
(10). Multilocus sequence typing (MLST) of the CR K. pneumoniae iso-
lates of the predominant rep-PCR types was performed as described pre-
viously (11). The sequences of seven housekeeping genes (rpoB, gapA,
mdh, pgi, phoE, infB and tonB) were compared to the MLST database
(http://www.pasteur.fr/recherche/genopole/PF8/mlst).
Genome sequencing. To generate a finished accurate CR K. pneu-
moniae blaNDM-1 genome, independent de novo assemblies were generated
from sequence data from Pacific Biosciences and Illumina instruments.
CR K. pneumoniae blaNDM-1 genomic DNA was sheared, SMRTbell librar-
ies were generated, XL polymerase-bound complexes were loaded onto
SMRT cells, and sequencing was performed with the RSII system as sug-
gested by the manufacturer (Pacific Biosciences, Menlo Park, CA). As-
semblies were generated with the Celera Assembler and then postpro-
cessed with Quiver for realignment and polishing as described previously
(12). In brief, we utilized the suggested hierarchical genome assembly
process, which consisted of (i) selecting long sequencing reads as seed
data, (ii) using seed sequences as references to recruit consensus shorter
reads, (iii) assembling long seed data and short reads with the Celera
Assembler adapted for SMRT sequencing data, (iv) polishing the assem-
bly with Quiver to generate consensus sequences, and (v) manually trim-
ming overlapping identical end regions to create circular finished chro-
mosomes and plasmids.
For independent sequence comparison, a Nextera library was gener-
ated from the same genomic DNA and sequenced to an 100 depth on
an Illumina MiSeq instrument; this was followed by assembly with MIRA
as described previously (13). Draft annotation was performed with the
RAST pipeline and finalized with PGAP.
Analysis. Univariate logistic regression was used to estimate associa-
tions between CR K. pneumoniae strain types and microbiological and
clinical variables. Cox proportional hazard modeling was used to estimate
associations between potential predictors and time to death in the hospi-
tal. The time in days from the first positive culture to death in the hospital
was displayed in a Kaplan-Meier plot. A log rank test was used to compare
groups. Patients were censored at the time of discharge or on postculture
day 30 if still in the hospital and alive. All of the analyses were performed
with JMP software (SAS Inc., Cary, NC).
Nucleotide sequence accession numbers. Sequences have been de-
posited in GenBank, and the accession numbers can be found via NCBI
BioSample record number 2777842.
RESULTS
Patients. During the study period, 251 individual patients were
included (Table 1 and Fig. 1). Patients were generally elderly (me-
dian age, 70 years; interquartile range [IQR], 58 to 81 years) and
had several comorbid conditions (median Charlson score, 4; IQR,
2 to 6). Of note, 71 patients (28%) were admitted from home,
whereas the remainder came from skilled-nursing facilities
(SNFs) (49%) or long-term acute-care facilities (10%) or were
transferred from other hospitals (13%).
CR K. pneumoniae infection and colonization. Urine (63%)
was the predominant anatomic source of CR K. pneumoniae (Fig.
2), followed by respiratory (12%), wound (11%), blood (10%),
and other (4%) samples. Patients culture sources grouped as
“other” included abscess (n  2), vascular catheter tip (n  3),
ascites (n  2), bile (n  2), and stool (n  1). Antibiotic use prior
to the first positive culture was common; only 29% had no docu-
mented antibiotic exposure in the preceding 14 days. CR K. pneu-
moniae infection was present in 45% of the patients. Of patients
with CR K. pneumoniae infections, 43/114 (38%) had nosocomial
infections, 48/114 (42%) had health care-associated infections,
and 23 (20%) had community-acquired infections.
Most (74%) of the patients with CR K. pneumoniae coloniza-
tions had urinary tract colonizations, and half of the patients with
infections had urinary tract infections. The use of a Foley catheter
was documented in 53 and 39% of the patients with CR K. pneu-
moniae urinary tract colonizations and infections, respectively.
The antibiotic susceptibilities determined are summarized in
Fig. 2. Colistin susceptibilities were determined for the first iso-
lates of 114 patients; of these, 8/114 (7%) were nonsusceptible. In
contrast, tigecycline nonsusceptibility was more common; 83/182
(45%) isolates tested were nonsusceptible to tigecycline. However,
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for most of these isolates (56/182, 31%) the MIC was 2 g/ml
(intermediate susceptibility). Three isolates that were colistin
nonsusceptible were also nonsusceptible to tigecycline (interme-
diate, n  1; resistant, n  2).
Outcomes. The outcomes of the index hospitalizations are
summarized in Table 2. Hospital stays were prolonged (median
length of stay [LOS], 9 days; IQR, 5 to 17 days) and complicated.
About half of the patients (51%) were admitted to the intensive
care unit (ICU), and the median ICU LOS in those admissions was
6 days (IQR, 3 to 15 days). Most of the patients were discharged to
SNFs (43%), and only 17% of the patients were discharged home.
Of the 71 patients who were admitted from home, only 48% could
be discharged home. Thirty-nine patients died, and an additional
six were discharged to hospice care. In patients with CR K. pneu-
moniae infections versus colonizations, the hospital (including
hospice care) mortality rate was 23% versus 14%.
Of the 26 patients with bacteremia, 21 (81%) received either
monotherapy (tigecycline [n  4], colistin [n  4], aminoglyco-
sides [n  3], or trimethoprim-sulfamethoxazole [n  1]) or
combination therapy (tigecycline-gentamicin [n  5], amikacin-
colistin [n  3], or tigecycline-colistin [n  1]). Five patients with
bloodstream infections died before antibiograms were available
and did not receive antibacterial therapy with activity against CR
K. pneumoniae.
Antibacterial therapy active against CR K. pneumoniae was
used in 65% of the patients with urinary tract infections and 60%
of the patients with other sources of infection. Of note, 46% of the
patients with urinary colonization were also treated with agents
active against CR K. pneumoniae.
In patients with CR K. pneumoniae infection (n  114), the
source of infection was associated with the time to death in the
hospital within 30 days of admission (Fig. 3). Variables associated
with the time to death in the hospital in an age-corrected Cox
proportional hazard model included severe acute disease, as de-
fined by a PBS of 4 (hazard ratio [HR], 3.82; 95% CI, 1.49 to
11.11; P  0.005) and a nonurinary source of infection (HR, 2.7;
95% CI, 1.04 to 8.49; P  0.040). Receipt of antibiotics with in
vitro susceptibility within 48 h of a positive culture was not asso-
ciated with improved survival in this analysis (HR, 1.46; 95% CI,
0.41 to 4.13; P  0.52).
Molecular strain typing and mechanisms of resistance. Mo-
lecular strain typing by rep-PCR was performed for all of the 113
patients whose CR K. pneumoniae isolates were available, i.e., 52
TABLE 1 Demographic characteristics of the patients in this study
Patient characteristic All Infected Colonized
Total no. 251 114 137
Median age, yr (IQR) 70 (58–81) 67 (54–81) 73 (64.5–83)
No. (%) female 150 (60) 67 (59) 83 (61)
No. (%) who were:
White, non-Hispanic 145 (58) 63 (55) 82 (60)
Black, non-Hispanic 95 (38) 49 (43) 46 (34)
Hispanic 7 (3) 2 (2) 5 (4)
Other 4 (2) 0 4 (3)
No. (%) with:
Diabetes mellitus 140 (56) 66 (58) 74 (54)
Heart diseasea 142 (57) 62 (55) 80 (58)
Renal insufficiency 65 (26) 31 (27) 34 (25)
COPDb 73 (29) 30 (27) 43 (31)
Malignancy 36 (14) 18 (16) 18 (13)
Dementia 54 (22) 22 (19) 32 (23)
Immunocompromise 25 (10) 14 (12) 11 (8)
Prednisone therapyc 12 (5) 6 (5) 6 (4)
Solid-organ transplant 10 (4) 5 (4) 5 (4)
HIV infection 2 (1) 2 (2) 0
Hematopoietic stem cell
transplant
1 (0) 1 (1) 0
Median Charlson comorbidity
index (IQR)
4 (2–6) 4 (2–6) 4 (2–6)
No. (%) from:
SNF 123 (49) 50 (44) 73 (53)
Home 71 (28) 34 (30) 37 (27)
Another hospital 32 (13) 20 (18) 12 (8)
Long-term acute-care facility 25 (10) 10 (9) 15 (11)
a Coronary artery disease and/or congestive heart failure.
b COPD, chronic obstructive pulmonary disease.























































































FIG 1 Flow diagram outlining the characteristics of the patients in this study. In each box, the origin of admission for the index hospitalization, the first culture
site, and whether the first culture represented infection or colonization are shown.
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patients with CR K. pneumoniae colonizations and 61 patients
with CR K. pneumoniae infections. The two most common types
were A (36/113, 29%) and B (52/113, 46%), which were both identi-
fied as belonging to MLST sequence type 258 (ST258). The remaining
22 isolates (19%) represented 16 different rep-PCR types, including
strains belonging to ST15, ST17, ST299, and ST395.
Carbapenemase genes were detected in isolates from 109/113
patients, while none of the carbapenemase genes tested (blaKPC,
blaNDM blaVIM, blaIMP, and blaOXA-48) were detected in the four
isolates tested. Furthermore, these four isolates did not phenotyp-
ically express a carbapenemase, according to a modified Hodge
test (data not shown); the carbapenem resistance of these isolates
is likely due to a combination of extended-spectrum beta-lacta-
mases (ESBLs) and changes in outer membrane proteins (14). All
but one of the carbapenemase-harboring isolates carried either
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FIG 2 (A) Numbers of colonizations and infections per anatomical site of CR K. pneumoniae-positive cultures. Percentages are the proportions of patient with
infections. (B) Selected antimicrobial susceptibility rates. Note that breakpoints defined by the CLSI were used for aminoglycosides and criteria set forth by the
EUCAST were used for colistin and tigecycline. TMP/SMX, trimethoprim-sulfamethoxazole.
TABLE 2 Outcome of first admission per patienta
Patient characteristic All Infected Colonized P valueb
Total no. 251 114 137
No. (%) at following location at time of culture: 0.48
Emergency department 66 (26) 26 (23) 40 (29)
Ward 108 (43) 50 (44) 58 (42)
ICU 77 (31) 38 (33) 39 (28)
Median PBS (IQR) 2 (1–4) 2 (1–4) 2 (0–4) 0.10
Median no. of days to first positive culture (IQR) 1 (0–4) 1 (0–6) 0 (0–4) 0.08
No. (%) with CR K. pneumoniae isolated:
Within first 24 h 124 (49) 54 (47) 70 (51)
On days 2–5 69 (27) 29 (25) 40 (29)
After day 5 58 (23) 31 (27) 27 (20)
Median LOS, days (IQR) 9 (5–17) 10 (6–20) 8 (5–15) 0.11
No. (%) with ICU admission 129 (51) 65 (57) 64 (47) 0.13
Median no. of days in ICU (IQR)a 6 (3–15) 7 (3.5–15.5) 6 (3–15) 0.31
No. (%) with:
Surgery 60 (24) 38 (33) 22 (16) 0.01
Renal insufficiency 91 (36) 43 (38) 48 (35) 0.69
Renal replacement therapy 46 (18) 24 (21) 22 (16) 0.33
Mechanical ventilation 85 (34) 47 (41) 38 (28) 0.03
Tracheostomy 39 (16) 17 (15) 22 (16) 0.86
No. (%) with following disposition: 0.05
Death/hospice 45 (18) 26 (23) 19 (14)
Home 43 (17) 19 (17) 24 (18)
SNF 107 (43) 39 (35) 68 (50)
Other 56 (22) 30 (26) 26 (19)
a For patients with any ICU admission.
b Fisher’s exact test for binomial variables, t test for normally distributed continuous variables, and likelihood ratio test for distributions.
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The remaining carbapenemase-harboring isolate tested posi-
tive for blaNDM-1, a sentinel finding in this geographic region. The
patient in whom this blaNDM-1-positive CR K. pneumoniae strain
was found was a male from Egypt who was admitted for cardiac
surgery. Nine days postoperatively, he developed abdominal pain,
turbid urine, a fever to 38.7°C, and leukocytosis. Urine analysis
showed more than 25 white cells per high-power field, and his
urine culture grew CR K. pneumoniae, as well as an ESBL-produc-
ing Escherichia coli strain that was susceptible to carbapenems. He
was treated with a single dose of gentamicin and 7 days of mero-
penem. His symptoms resolved, and he was discharged 8 days
after his first positive CR K. pneumoniae culture. He did not have
a readmission during the study period. No other CR K. pneu-
moniae isolates obtained during the study period tested positive
for blaNDM-1, suggesting that no transmission to other patients
occurred (see below).
As ST258 is the most common CR K. pneumoniae sequence
type worldwide, we further explored clinical and microbiological
differences between the A and B types identified by rep-PCR
(Table 3). Antibiotic susceptibility patterns were significantly as-
sociated with rep-PCR strain types; type A CR K. pneumoniae was
more likely than type B to be tigecycline (odds ratio [OR], 5.34;























Days since positive culture
blood 26 17 9 6 4 2 0
31 25 16 9 8
57 43 20 13 3 0 0
p=0.015
blood
FIG 3 Kaplan-Meier survival curves showing times from the first positive
culture to death in the hospital for patients with CR K. pneumoniae infections
by source of infection, censoring at 30 days, or time of discharge, whichever
occurred first (P  0.015 by log rank test).
TABLE 3 Comparison of patients with rep-PCR type A and B strains
Patient characteristic A B ORa (95% CI) P valueb
Total no. 39 52
No. (%) with:
Any carbapenemase 39 (100) 51 (98)
KPC-2 36 (92) 2 (4) 294.00 (58.16–2552.68) 0.001
KPC-3 3 (7) 49 (96) 0.00 (0.00–0.02) 0.001
No. (%) with isolate from: 0.135
Urine 19 (49) 36 (69)
Blood 11 (28) 8 (15) 2.61 (0.90–7.81)
Other 9 (23) 8 (15) 2.13 (0.70–6.57)
No. (%) infected 22 (56) 27 (51) 1.20 (0.52–2.78) 0.67
No. with susceptible isolates/no. with isolates tested (%)
Colistin 32/35 (91) 37/39 (95) 0.57 (0.07–3.69) 0.66
Tigecycline 23/25 (92) 28/41 (68) 5.34 (1.30–36.41) 0.018
Amikacin 7/18 (39) 42/48 (88) 0.09 (0.02–0.31) 0.001
Gentamicin 30/38 (79) 7/52 (13) 24.11 (8.39–79.38) 0.001
Trimethoprim-sulfamethoxazole 9/36 (25) 22/52 (42) 0.45 (0.17–1.13) 0.091
No. (%) from:
SNFs 9 (23) 25 (48) 0.043
Home 15 (38) 15 (29) 2.78 (0.99–8.16)
Other 15 (38) 12 (23) 3.47 (1.21–10.55)
No. (%) with strain present at admission 14 (36) 28 (54) 0.48 (0.20–1.11) 0.088
Median LOS (IQR) 12 (6–32) 8 (5–19.75) 1.02c (1.00–1.04) 0.043
No. (%) with following disposition:
Death/hospice 11 (28) 10 (19) 0.72
Home 7 (18) 13 (25) 0.49 (0.13–1.69)
SNF 15 (38) 20 (38) 0.68 (0.22–2.02)
Other 6 (15) 9 (17) 0.61 (0.15–2.29)
a OR for A versus B.
b Univariate logistic regression.
c OR per day increase in LOS.
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CI, 8.39 to 79.38; P  0.001) susceptible and less likely to be sus-
ceptible to amikacin (OR, 0.09; 95% CI, 0.02 to 0.31; P  0.001).
blaKPC was present in all of the type A and in all but one of the type
B CR K. pneumoniae isolates. KPC-2 and KPC-3 were the two
carbapenemases found. A significant association between the rep-
PCR type and the KPC enzyme found was also discovered; type A
CR K. pneumoniae isolates were associated with KPC-2, whereas
type B isolates were associated with KPC-3 (OR, 294.00; 95% CI,
58.16 to 2552.68; P  0.001).
On clinical grounds, patients with type B CR K. pneumoniae
were more likely to be admitted from an SNF (OR, 3.09; 95% CI,
1.26 to 8.08; P  0.013) and to have a shorter LOS (OR, 0.98/day
increase; 95% CI, 0.95 to 1.00; P  0.043) than patients with type
A CR K. pneumoniae.
Genome sequencing of blaNDM-1-producing strain. As the
isolation of a blaNDM-1-producing CR K. pneumoniae strain rep-
resented a “sentinel event” in our community, the bacterial ge-
nome of this strain was sequenced in order to provide a reference
sequence for the development of clinical diagnostics for these
newly emerging organisms. In brief, the chromosome of this K.
pneumoniae strain is 5,284,834 nucleotides (nt) in length, has a
57% GC content, and was determined to belong to ST395 (11),
which is unique in our region.
Two plasmids were also found in this strain. Plasmid 1 was
94,656 nt long and present at 1.6 relative to the chromosome.
Plasmid 2 carried the blaNDM-1 gene, was 118,033 nt long, and was
present at 2.2 relative to the chromosome. Plasmid 2 is an IncF
replicon with similarity to other IncF plasmids, like pKPN4 (ac-
cession no. CP000649.1). Notably, the blaNDM-1 gene environ-
ment is adjacent to a bleomycin resistance protein-encoding gene,
a finding that is common in blaNDM-1-producing strains and is
thought to impact the overall survival value of this strain (15).
DISCUSSION
Through this comprehensive effort, a clear picture of the origin,
acute and chronic morbidity, hospitalization characteristics, and
outcomes of hospitalized patients with CR K. pneumoniae in our
region has emerged. Hospitalized patients with CR K. pneumoniae
originate primarily from the long-term care population (16–19).
Skilled nursing and long-term acute-care facilities clearly play an
important role in the epidemiology of CR K. pneumoniae.
Whether this is simply a reflection of the overlap of risk factors for
multidrug-resistant (MDR) organisms with risk factors for admis-
sion to long-term care facilities, such as comorbidities and inva-
sive device use, or whether this is an indication of transmission
within long-term care facilities remains to be seen (19).
Importantly, a substantial minority of the patients we studied
were admitted from home. These patients may have had prior
health care or long-term care exposure but were admitted from
home for their index hospitalization during the study period. This
has an impact for hospitals that screen patients for MDR organ-
isms upon admission. It may not be sufficient to screen only those
who are admitted from other hospitals.
Patients with CR K. pneumoniae are both chronically and
acutely ill and have prolonged and complicated hospitalizations.
Moreover, patients are unlikely to be discharged home, and the
overall hospital mortality rate was 16%, with an additional 2% of
the patients discharged to hospice care. In patients with CR K.
pneumoniae infections, clinical factors associated with time to
death in the hospital included expected variables such as the
source of infection and severe acute illness, as previously de-
scribed (7).
A troublesome trend was observed in the susceptibilities of CR
K. pneumoniae to the “last-resort” antimicrobials colistin, tigecy-
cline, and aminoglycosides. Colistin nonsusceptibility occurred in
a small subset of the patients, and tigecycline and aminoglycoside
nonsusceptibility was common. Most concerning was the fact that
two patients presented with colistin- and tigecycline-resistant iso-
lates. This is clear evidence that new antimicrobials directed
against CR K. pneumoniae are urgently needed, as well as ongoing
efforts to stem the rise in MDR pathogens.
The great majority of isolates belonged to ST258, which is the
predominant strain of CR K. pneumoniae in the United States and
worldwide (20). Within this sequence type, however, we were able
to further identify two predominant separate strains by rep-PCR.
Importantly, these two strains differed in their susceptibilities to
aminoglycosides and tigecycline. In addition, differences in clini-
cal outcomes were observed in patients possessing the two strains.
A very important finding in our cohort was the presence of a
single patient during the study period who was infected with
blaNDM-1-harboring CR K. pneumoniae. NDM-1 remains an un-
common mechanism of carbapenem resistance in the United
States but is widespread in India, Pakistan, Bangladesh, and other
parts of the world (21, 22). Fortunately, continued vigilance
through this network has not detected further evidence of dissem-
ination of blaNDM-1-harboring CR K. pneumoniae in our region.
Our study has several limitations. While we have used stan-
dardized definitions of infection, the distinction between infec-
tion and colonization remains a challenge. We suspect that at least
some patients with infections were misclassified as having coloni-
zations. However, when standardized definitions are used, the
likelihood of the patients with colonizations being misclassified as
having infections is low. In addition, our definition of CR K. pneu-
moniae may have missed some non-KPC-producing K. pneu-
moniae isolates with lower carbapenem MICs. The lack of active
surveillance means that we are likely to underestimate the true
number of CR K. pneumoniae-colonized patients. We categorized
20% of the infections as community acquired. However, data on
prior health care exposures that may have preceded the current
admission from home are not available.
The heterogeneity of antibiotic treatment in our cohort pre-
cluded comparative effectiveness analysis. The observed lack of
association between the risk of death and CR K. pneumoniae-di-
rected treatment in the first 48 h is probably secondary to both
confounding by indication and other unmeasured covariables and
the limited efficacy of currently available agents. Several studies
have provided preliminary data suggestive of a benefit of combi-
nation therapy (23, 24).
Our findings illustrate the ongoing and increasing threat that
CR K. pneumoniae poses to our vulnerable population and the
clear benefits of real-time surveillance and molecular epidemiol-
ogy in tracking the dissemination and clinical impact of resistance
genes in specific pathogens.
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